Skip to main content

Clinical Trials Using Cytarabine

Review the clinical trials studying cytarabine on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 98

Talazoparib in Combination with Chemotherapy for the Treatment of Pediatric Patients with Relapsed or Refractory AML, the PARPAML Trial
Status: Active
Location: 10 locations
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
Status: Active
Location: 8 locations
Chemotherapy with Radiation Therapy or Autologous Stem Cell Rescue for the Treatment of Embryonal Tumor with Multilayered Rosettes in Patients with Gross-Total Resection, Residual Disease, or Metastatic Disease
Status: Active
Location: 7 locations
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Status: Active
Location: 8 locations
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, “7+3”) for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Status: Active
Location: 6 locations
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Status: Active
Location: 3 locations
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Status: Active
Location: 3 locations
Adding Dasatinib or Venetoclax to Standard Chemotherapy for the Treatment in Children with T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoma or Mixed Phenotype Acute Leukemia, the SJALL23T Trial
Status: Active
Location: 3 locations
Revumenib with Cytarabine, Daunorubicin and Midostaurin for the Treatment of Patients with NPM1 and FLT3 Mutated Acute Myeloid Leukemia
Status: Active
Location: 3 locations
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Status: Active
Location: 3 locations
Ruxolitinib in Combination with Standard Chemotherapy in Treating Adolescents and Young Adults with Ph-Like Acute Lymphoblastic Leukemia
Status: Active
Location: 3 locations
Risk Categorization for Treatment Assignment in Children and Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma, the INITIALL Trial
Status: Active
Location: 3 locations
Venetoclax in Combination with Cladribine and Cytarabine Alternating with Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Status: Active
Location: 2 locations
Venetoclax plus CLAG-M for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: 2 locations
Updated Chemotherapy Regimen for the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Status: Active
Location: 2 locations
Inotuzumab Ozogamicin and Blinatumomab with Standard Chemotherapy in Treating Newly Diagnosed Patients with B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Status: Active
Location: 2 locations
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: 2 locations
Fludarabine, Idarubicin and Venetoclax with Standard Chemotherapy for the Treatment of Childhood Acute Myeloid Leukemia and Myeloid Sarcoma, UPDATE AML Trial
Status: Active
Location: 2 locations
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients with Previously Untreated Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine, Cytarabine, and Decitabine With or Without Venetoclax and Gilteritinib in Treating Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine, Low Dose Cytarabine, Venetoclax, and Azacitidine for the Treatment of Higher-Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome/Myeloproliferative Neoplasms
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Induction and Consolidation with Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Itacitinib or Ruxolitinib to Improve Efficacy in Patients with Diffuse Large B-Cell Lymphoma Receiving Treatment with CAR T-cell Therapy
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida